A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
NCT ID: NCT00922090
Last Updated: 2010-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1494 participants
OBSERVATIONAL
2009-07-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
NCT00779506
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
NCT00882518
Seroquel Long-Term NIS for Schizophrenia Patients
NCT00523783
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
NCT00954122
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
NCT00640601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are taking Seroquel XR no longer than 1 month
* Patients who get antipsychotics monotherapy at least 1 week before enroll in this study
Exclusion Criteria
* Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I diagnosis,concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation.
* Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Korea
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JoonWoo Bahn, MD, PhD
Role: STUDY_DIRECTOR
AstraZeneca Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Busan, , South Korea
Research Site
Daegu, , South Korea
Research Site
Goyang, , South Korea
Research Site
Gwangju, , South Korea
Research Site
Incheon, , South Korea
Research Site
Jeju City, , South Korea
Research Site
Kyung Gi, , South Korea
Research Site
Kyungju, , South Korea
Research Site
Kyungnam, , South Korea
Research Site
Namyangju, , South Korea
Research Site
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NKR-SER-2009/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.